Drug Patent Watch

APRIL 13, 2024

Annual Drug Patent Expirations for VOSEVI Vosevi is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are nineteen… Source

52

52

Drug Patent Watch

FEBRUARY 8, 2024

Annual Drug Patent Expirations for VEKLURY Veklury is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are thirteen… The post New patent for Gilead Sciences drug VEKLURY appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

59

59

Drug Patent Watch

FEBRUARY 16, 2024

Annual Drug Patent Expirations for MYFEMBREE Myfembree is a drug marketed by Myovant Sciences and is included in one NDA. There are six patents… The post New patent expiration for Myovant Sciences drug MYFEMBREE appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

59

59

Drug Patent Watch

MARCH 22, 2024

Annual Drug Patent Expirations for VEKLURY Veklury is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are thirteen… Source

52

52

Drug Patent Watch

MARCH 21, 2024

Annual Drug Patent Expirations for BIKTARVY Biktarvy is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from two suppliers. There are twelve… Source

52

52

Drug Patent Watch

JANUARY 15, 2024

Annual Drug Patent Expirations for MYFEMBREE Myfembree is a drug marketed by Myovant Sciences and is included in one NDA. There are six patents… The post New patent for Myovant Sciences drug MYFEMBREE appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

59

59

Drug Patent Watch

MARCH 20, 2024

Annual Drug Patent Expirations for VEKLURY Veklury is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are thirteen… Source

52

52

Drug Patent Watch

JANUARY 27, 2024

Annual Drug Patent Expirations for MYFEMBREE Myfembree is a drug marketed by Myovant Sciences and is included in one NDA. There are six patents… The post New patent expiration for Myovant Sciences drug MYFEMBREE appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

59

59

Drug Patent Watch

DECEMBER 13, 2023

Annual Drug Patent Expirations for MYFEMBREE Myfembree is a drug marketed by Myovant Sciences and is included in one NDA. There are six patents… The post New patent for Myovant Sciences drug MYFEMBREE appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

59

59

Drug Patent Watch

DECEMBER 13, 2023

Annual Drug Patent Expirations for ORGOVYX Orgovyx is a drug marketed by Myovant Sciences and is included in one NDA. There are eight patents… The post New patent for Myovant Sciences drug ORGOVYX appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

59

59

Drug Patent Watch

JANUARY 12, 2024

Annual Drug Patent Expirations for STRIBILD Stribild is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are eleven… The post New patent expiration for Gilead Sciences drug STRIBILD appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

59

59

Drug Patent Watch

JANUARY 12, 2024

Annual Drug Patent Expirations for COMPLERA Complera is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are eight… The post New patent expiration for Gilead Sciences drug COMPLERA appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

59

59

Drug Patent Watch

JANUARY 12, 2024

Annual Drug Patent Expirations for ATRIPLA Atripla is a drug marketed by Gilead Sciences and is included in one NDA. There are seven patents… The post New patent expiration for Gilead Sciences drug ATRIPLA appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

59

59

Outsourcing Pharma

APRIL 8, 2024

In an exclusive interview with Dr Vanessa Zann, (pictured below) executive drug development consultant at Quotient Sciences, OSP delved into the forefront of pharmaceutical research and development.

Drug Development 59

Drug Development 59

Drug Patent Watch

OCTOBER 26, 2023

Annual Drug Patent Expirations for MYFEMBREE Myfembree is a drug marketed by Myovant Sciences and is included in one NDA. There are four patents… The post New patent for Myovant Sciences drug MYFEMBREE appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

59

59

Drug Patent Watch

OCTOBER 26, 2023

Annual Drug Patent Expirations for ORGOVYX Orgovyx is a drug marketed by Myovant Sciences and is included in one NDA. There are seven patents… The post New patent for Myovant Sciences drug ORGOVYX appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

59

59

Outsourcing Pharma

APRIL 8, 2024

In an exclusive interview with Dr Vanessa Zann, (pictured below) executive drug development consultant at Quotient Sciences, OSP delved into the forefront of pharmaceutical research and development.

Drug Development 60

Drug Development 60

Outsourcing Pharma

DECEMBER 19, 2023

The US contract development and manufacturing organization (CDMO) Agno Pharma has taken over compatriot firm Lubrizol Particle Sciences to increase its drug product formulation offerings.

91

91

Drug Patent Watch

OCTOBER 5, 2023

Annual Drug Patent Expirations for BIKTARVY Biktarvy is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are eleven… The post New patent for Gilead Sciences drug BIKTARVY appeared first on DrugPatentWatch - Make Better Decisions. It is available from two suppliers.

59

59

Drug Patent Watch

AUGUST 24, 2023

Annual Drug Patent Expirations for EPCLUSA Epclusa is a drug marketed by Gilead Sciences Inc and is included in two NDAs. There are fifteen… The post New patent for Gilead Sciences drug EPCLUSA appeared first on DrugPatentWatch - Make Better Decisions. It is available from two suppliers.

52

52

Drug Patent Watch

AUGUST 16, 2023

Annual Drug Patent Expirations for EPCLUSA Epclusa is a drug marketed by Gilead Sciences Inc and is included in two NDAs. There are fifteen… The post New patent for Gilead Sciences drug EPCLUSA appeared first on DrugPatentWatch - Make Better Decisions. It is available from two suppliers.

52

52

Pharmaceutical Technology

JANUARY 23, 2024

Inhalation Sciences has entered into a collaboration with Germany-based Actarmo Medical for respiratory drug development services.

Drug Development 52

Drug Development 52

Drug Patent Watch

AUGUST 27, 2021

Annual Drug Patent Expirations for EPCLUSA Epclusa is a drug marketed by Gilead Sciences Inc and is included in two NDAs. The post New patent for Gilead Sciences drug EPCLUSA appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier. There are twenty-six….

98

98

Drug Patent Watch

JUNE 16, 2021

Annual Drug Patent Expirations for VEKLURY Veklury is a drug marketed by Gilead Sciences Inc and is included in one NDA. The post New patent for Gilead Sciences drug VEKLURY appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier. There are eight….

98

98

STAT

APRIL 25, 2024

University of Washington professor David Baker has made a name for himself by borrowing computer science concepts like machine learning and artificial intelligence to solve problems in biology. Now Baker is pushing forward in a different area of drug discovery research.

Compounding 343

Compounding Drug Development 343

Drug Patent Watch

MARCH 17, 2023

Annual Drug Patent Expirations for ORGOVYX Orgovyx is a drug marketed by Myovant Sciences and is included in one NDA. There are six patents… The post New patent for Myovant Sciences drug ORGOVYX appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

52

52

Drug Patent Watch

APRIL 10, 2023

Annual Drug Patent Expirations for COMPLERA Complera is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are nine… The post New patent expiration for Gilead Sciences drug COMPLERA appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

52

52

Drug Patent Watch

APRIL 10, 2023

Annual Drug Patent Expirations for ODEFSEY Odefsey is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are seven… The post New patent expiration for Gilead Sciences drug ODEFSEY appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

52

52

Drug Patent Watch

MAY 3, 2021

Annual Drug Patent Expirations for ATRIPLA Atripla is a drug marketed by Gilead Sciences and is included in one NDA. The post New patent expiration for Gilead Sciences drug ATRIPLA appeared first on DrugPatentWatch - Make Better Decisions. It is available from two suppliers. There are nine patents….

90

90

STAT

MAY 13, 2024

Want to stay on top of the science and politics driving biotech today?  Today we learn whether AI might help hasten the development of n-of-1 therapies (hint: not yet), explore why the FDA hasn’t offered Orange Book guidance on drug-device combinations, and talk about CRISPR.

Drug Pricing 239

Drug Pricing Drug Development 239

Pharmaceutical Technology

SEPTEMBER 15, 2023

Charles River has signed a multi-programme collaboration agreement with Related Sciences (RS) for the AI-powered drug platform, Logica.

59

59

Drug Patent Watch

DECEMBER 7, 2022

Annual Drug Patent Expirations for VEKLURY Veklury is a drug marketed by Gilead Sciences Inc and is included in one NDA. The post New patent for Gilead Sciences drug VEKLURY appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier. There are eleven….

52

52

STAT

MARCH 14, 2024

What happens when an approved drug doesn’t work? Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. Why don’t patients want gene therapy? And is MASH still a big deal? Read the rest…

Drug Development 281

Drug Development 281

Drug Patent Watch

NOVEMBER 14, 2022

Annual Drug Patent Expirations for VEMLIDY Vemlidy is a drug marketed by Gilead Sciences Inc and is included in one NDA. The post New patent for Gilead Sciences drug VEMLIDY appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier. There are four….

52

52

STAT

MAY 10, 2024

Want to stay on top of the science and politics driving biotech today?  We see in a KFF survey that a majority of Americans want obesity drugs to be covered by Medicare, offer up a cool new podcast, and more.   Sign up  to get our biotech newsletter in your inbox.

Drug Pricing 279

Drug Pricing Drug Development 279

Drug Patent Watch

SEPTEMBER 2, 2022

Annual Drug Patent Expirations for MYFEMBREE Myfembree is a drug marketed by Myovant Sciences and is included in one NDA. There are four patents protecting this drug. This drug has…. The post New patent for Myovant Sciences drug MYFEMBREE appeared first on DrugPatentWatch - Make Better Decisions.

52

52

STAT

APRIL 10, 2024

Vertex Pharmaceuticals will buy Alpine Immune Sciences, a maker of protein-based medicines that harness the immune system, for $4.9 The drug will enter Phase 3 clinical development in the second half of the year. billion, the companies announced Wednesday. It is the largest acquisition in Vertex’s history.

Immunity 353

Immunity Immunization 353